Aptose Biosciences (APTO) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free APTO Stock Alerts $1.22 +0.06 (+5.17%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAptose Biosciences Inc. (NASDAQ:APTO) Sees Large Decrease in Short Interestamericanbankingnews.com - April 26 at 4:02 AMAptose Biosciences Inc. (NASDAQ:APTO) Receives Average Rating of "Buy" from Analystsamericanbankingnews.com - April 17 at 2:24 AMAptose Biosciences target cut, maintains buy rating on new drug developmentinvesting.com - March 29 at 10:53 AMAptose Biosciences, Inc.: Aptose Reports Results for the Fourth Quarter and Full Year 2023finanznachrichten.de - March 28 at 1:00 AMAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 27 at 9:59 AMEdgewood secures $20m in Series A for clinical development of cancer therapymsn.com - March 27 at 4:58 AMRecap: Aptose Biosciences Q4 Earningsbenzinga.com - March 27 at 4:58 AMAptose Reports Results for the Fourth Quarter and Full Year 2023globenewswire.com - March 26 at 4:01 PMAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024globenewswire.com - March 18 at 4:30 PMThis Aptose Biosciences Insider Increased Their Holding In The Last Yearfinance.yahoo.com - January 29 at 8:49 AMAptose Biosciences Shares Drop 11% After Private, Public Offeringsmarketwatch.com - January 26 at 6:27 PMAptose Prices Offering Of About 4.91 Mln Shares At $1.71/Share, $4 Private Placement With Hanmimarkets.businessinsider.com - January 26 at 6:27 PMAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceuticalfinance.yahoo.com - January 26 at 6:27 PMWhy Is Aptose Biosciences (APTO) Stock Down Today?investorplace.com - January 26 at 10:43 AMAptose Biosciences Stock (NASDAQ:APTO), Guidance and Forecastbenzinga.com - December 21 at 1:08 AMAptose Biosciences Inc APTOmorningstar.com - December 5 at 10:43 PMAptose Biosciences files to sell ordinary shares, warrantsmsn.com - December 4 at 10:00 AMAptose Biosciences, Inc.: Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Rolefinanznachrichten.de - December 1 at 7:47 AMAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcriptseekingalpha.com - November 12 at 7:59 PMAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning Callsbenzinga.com - November 11 at 8:49 PMAptose Biosciences: Q3 Earnings Insightsbenzinga.com - November 10 at 11:13 PMPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph Pantginismarkets.businessinsider.com - November 10 at 11:13 PMAptose Biosciences GAAP EPS of -$1.76 beats by $0.22msn.com - November 9 at 8:40 PMOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)markets.businessinsider.com - November 1 at 5:32 AMPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy Ratingmarkets.businessinsider.com - November 1 at 5:32 AMAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinibfinance.yahoo.com - October 30 at 10:18 AMAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conferencefinance.yahoo.com - October 16 at 8:22 AMAptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)theglobeandmail.com - October 12 at 5:32 PMCompanies Like Aptose Biosciences (TSE:APS) Could Be Quite Riskyfinance.yahoo.com - September 8 at 3:54 PMHANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.finance.yahoo.com - September 7 at 6:50 PMExpert Ratings for Aptose Biosciencesmarkets.businessinsider.com - September 7 at 6:50 PMShort Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 12.8%marketbeat.com - August 29 at 4:03 AMAptose to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 24 at 10:00 AMClosing Bell: Aptose Biosciences Inc down on Tuesday (APS)theglobeandmail.com - August 23 at 6:59 PMAptose Biosciences (NASDAQ: APTO)fool.com - August 18 at 2:01 AMRBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Knowmarkets.businessinsider.com - August 11 at 7:33 PMRoyal Bank of Canada Cuts Aptose Biosciences (NASDAQ:APTO) Price Target to $23.00marketbeat.com - August 11 at 2:23 PMAptose Biosciences Inc. (NASDAQ:APTO) Receives Consensus Rating of "Buy" from Analystsmarketbeat.com - August 11 at 10:49 AMAptose Biosciences GAAP EPS of -$2.27 misses by $0.34msn.com - August 11 at 3:19 AMAptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90msn.com - August 2 at 5:02 PMAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023finance.yahoo.com - July 28 at 2:05 AMAPTO - Aptose Biosciences Inc.finance.yahoo.com - June 27 at 11:27 PMAptose Biosciences Meets Nasdaq Minimum Bid Price Compliancefinance.yahoo.com - June 26 at 6:09 PMAptose Shares Up 11% After Study Presentation, Analysts' Target Boostsmarketwatch.com - June 12 at 7:46 PMOppenheimer Maintains Outperform on Aptose Biosciences, Raises Price Target to $50benzinga.com - June 12 at 2:46 PMAptose Biosciences shares are trading higher after multiple firms raised their respective price targets.benzinga.com - June 12 at 2:46 PMJonesTrading Keeps Their Buy Rating on Aptose Biosciences (APTO)markets.businessinsider.com - June 10 at 8:43 PMAptose Biosciences updates on reverse stock splitmsn.com - June 5 at 10:04 AMAptose Biosciences, Inc.: Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholdersfinanznachrichten.de - May 24 at 1:37 PMCaspase 3 Market Business Overview and Growth Forecast by 2030marketwatch.com - May 17 at 7:16 AM Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. APTO Media Mentions By Week APTO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APTO News Sentiment▼0.500.32▲Average Medical News Sentiment APTO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APTO Articles This Week▼21▲APTO Articles Average Week Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AIM ImmunoTech News Today Evaxion Biotech A/S News Today ZIVO Bioscience News Today Senti Biosciences News Today Pluri News Today Coeptis Therapeutics News Today Windtree Therapeutics News Today Inhibikase Therapeutics News Today BioCardia News Today Organovo News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APTO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
